Dasatinib Monohydrate: Multitargeted Tyrosine Kinase Inhibitor for CML and Tumor Microenvironment Research

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a nanomolar-potency, multitargeted ATP-competitive kinase inhibitor that blocks ABL, SRC, KIT, PDGFR, and related tyrosine kinases, including imatinib-resistant BCR-ABL isoforms (IC₅₀ = 3.0 nM for BCR-ABL, 0.55 nM for SRC) [APExBIO]. It is FDA-approved for all phases of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) since 2006 [FDA]. Dasatinib demonstrates broad-spectrum antiproliferative activity in hematologic and solid tumor lines in vitro and in vivo, including in assembloid models that simulate tumor–stroma interactions (Shapira-Netanelov et al., 2025). Its high solubility in DMSO (≥25.3 mg/mL) and robust performance in mouse models make it a key tool for kinase pathway dissection and drug resistance research. APExBIO provides high-purity Dasatinib Monohydrate (SKU: B5954) for advanced translational and personalized oncology studies.

Biological Rationale

Tyrosine kinase signaling is central to proliferation and survival in hematological malignancies and many solid tumors. The BCR-ABL fusion protein, resulting from the Philadelphia chromosome translocation, drives CML and Ph+ ALL by constitutively activating ABL kinase pathways (Shapira-Netanelov et al., 2025). Imatinib resistance, often due to BCR-ABL mutations, necessitated the development of more potent, broad-spectrum kinase inhibitors. Dasatinib Monohydrate targets both wild-type and mutant BCR-ABL, as well as other critical kinases (SRC, KIT, PDGFR), making it foundational for research into leukemia pathogenesis, resistance mechanisms, and tumor microenvironment modulation. Recent advancements in assembloid models (integrating tumor organoids and stromal subpopulations) have increased demand for inhibitors like Dasatinib that can interrogate both tumor-intrinsic and microenvironmental pathways (Shapira-Netanelov et al., 2025).

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate is a multitargeted, ATP-competitive inhibitor of tyrosine kinases. It binds to the ATP-binding site of ABL, SRC family kinases, KIT, and PDGFR, among others. This binding prevents phosphorylation and downstream signaling required for cell proliferation and survival. Its IC₅₀ values are 0.55 nM for SRC and 3.0 nM for BCR-ABL [APExBIO]. Dasatinib inhibits BCR-ABL kinase activity even in the presence of mutations conferring imatinib resistance, except for the T315I gatekeeper mutation (Shapira-Netanelov et al., 2025). It also disrupts SRC-family kinase signaling, which supports tumor cell migration, invasion, and stromal interactions. In assembloid and co-culture models, Dasatinib modulates both tumor cell-intrinsic and microenvironment-dependent signaling, altering gene expression and drug sensitivity profiles. The compound is not effective on non-kinase-driven tumors or those reliant on non-targeted pathways.

Evidence & Benchmarks

• Dasatinib Monohydrate inhibits BCR-ABL kinase activity in vitro with an IC₅₀ of 3.0 nM (buffered kinase assay, pH 7.4, 25°C) (APExBIO).
• In cell viability assays, Dasatinib reduces proliferation of CML and Ph+ ALL cell lines at 10–50 nM (48–72 h incubation, serum-containing media) (Shapira-Netanelov et al., 2025).
• Dasatinib is active against imatinib-resistant BCR-ABL mutants (except T315I) in both in vitro studies and mouse xenograft models (Shapira-Netanelov et al., 2025).
• In mouse models of BCR-ABL-driven leukemia, daily oral Dasatinib (15–50 mg/kg) reduces disease markers and bioluminescence by >80% versus controls (n=5 per group, 21 days) (APExBIO).
• Integration of Dasatinib in assembloid models reveals altered gene expression and drug sensitivity unique to tumor–stroma co-cultures, compared to monocultures (Shapira-Netanelov et al., 2025).

Applications, Limits & Misconceptions

Dasatinib Monohydrate (B5954) is validated for research on:

• Chronic myeloid leukemia (CML) and Ph-positive ALL cell lines and patient samples.
• Imatinib-resistant BCR-ABL isoforms (except T315I).
• Kinase pathway mapping in both hematological and solid tumors.
• Preclinical assembloid models for tumor–stroma interaction and drug response profiling (Shapira-Netanelov et al., 2025).

This article extends prior coverage in "Dasatinib Monohydrate: Advanced Applications in Tumor Microenvironment" by providing quantitative, DOI-backed benchmarks for assembloid models and clarifying key resistance boundaries. For a broader workflow guide, "Advancing CML & Kinase Pathway Research" details experimental optimizations; here, we focus on validated comparative data and clinical translation. Finally, "Unlocking Tumor–Stroma Interactions" discusses mechanistic hypotheses—in contrast, this dossier restricts claims to peer-reviewed, verifiable findings.

Common Pitfalls or Misconceptions

• Dasatinib does not inhibit BCR-ABL T315I mutants at clinically relevant concentrations (Shapira-Netanelov et al., 2025).
• It is insoluble in ethanol and water; use DMSO (≥25.3 mg/mL) for stock solutions (APExBIO).
• Long-term storage of reconstituted solutions (>1 week) at >-20°C reduces potency; prepare fresh aliquots for each experiment.
• Dasatinib is not selective for BCR-ABL; off-target inhibition of SRC, KIT, and PDGFR is substantial—interpret pathway data accordingly.
• Its efficacy in non-tyrosine kinase-driven tumors is minimal; verify target pathway dependence before use.

Workflow Integration & Parameters

APExBIO's Dasatinib Monohydrate (B5954) is supplied as a solid, MW = 506.02, formula C₂₂H₂₈ClN₇O₃S. Store at -20°C, protected from light. Prepare DMSO stocks at 10–25 mg/mL; dilute in cell culture media for in vitro use (final DMSO ≤0.1%). For in vivo studies, dissolve in vehicle (e.g., 20% hydroxypropyl-β-cyclodextrin) and administer by oral gavage at 10–50 mg/kg/day. Use within one week of reconstitution. Monitor for off-target effects via pathway analysis. For assembloid and co-culture models, titrate concentrations (5–100 nM) to avoid stromal toxicity and maintain physiological relevance (Shapira-Netanelov et al., 2025).

Conclusion & Outlook

Dasatinib Monohydrate remains a mainstay for dissecting kinase-driven malignancies and tumor–stroma crosstalk. Its nanomolar potency and broad kinase profile support studies into drug resistance, microenvironmental modulation, and personalized therapeutic screening. As advanced assembloid models gain traction, validated, high-purity reagents from APExBIO ensure reproducibility and translational relevance. For full technical details and ordering, consult the Dasatinib Monohydrate product page.